Results 241 to 250 of about 1,207,145 (299)

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Current landscape of CAR-therapy for osteosarcoma and rhabdomyosarcoma. [PDF]

open access: yesFront Immunol
Stavrou M   +3 more
europepmc   +1 more source

Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors. [PDF]

open access: yesCancer Immunol Res
Brea EJ   +35 more
europepmc   +1 more source

The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies.

open access: yesBiochim Biophys Acta Rev Cancer
Krawczyk M   +3 more
europepmc   +1 more source

Spectroscopic studies of southern-hemisphere cepheids: WW Car, SX Car, UZ Car, UY Car, GX Car, HW Car, YZ Car

Astronomy Letters, 2011
For seven faint southern Cepheids (WW Car, SX Car, UZ Car, UY Car, GX Car, HW Car, YZ Car), we have determined their atmospheric parameters and chemical composition for the first time based on ten high-resolution (R = 50 000) spectra taken with the 1.5-m Hexapod telescope at the Joint Observatory of the Northern Catholic University (Antofagasta, Chile)
I. A. Usenko   +7 more
openaire   +1 more source

Home - About - Disclaimer - Privacy